MULTIDRUG-RESISTANT TUBERCULOSIS: What Nurses Should Know. Felissa R. Lashley, RN, PhD, FAAN, FACMG Professor , College of Nursing, and Interim Director, Nursing Center for Bioterrorism and Infectious Disease Preparedness, College of Nursing Rutgers, The State University of New Jersey
Related searches for MULTIDRUG-RESISTANT TUBERCULOSIS: What Nurses Should Know
Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.
Felissa R. Lashley, RN, PhD, FAAN, FACMG
Professor, College of Nursing, and
Interim Director, Nursing Center for Bioterrorism and Infectious Disease Preparedness, College of Nursing
Rutgers, The State University of New Jersey
This module is designed to highlight important information about multidrug resistant tuberculosis (MDR-TB). MDR-TB is also considered to be a potential agent for bioterrorism and is considered as a possible Category C bioterrorism agent by the Centers for Disease Control and Prevention (CDC). This module was supported in part by USDHHS, HRSA Grant No. T01HP01407.
be pulmonary or extrapulmonary.
form in developed countries.
Cough (usually productive and maybe bloody) resistance are
Chills at night
Dull, aching chest pain or tightness
Symptoms of extrapulmonary TB depend on the organ system involved but may include systemic symptoms such as malaiseSymptoms of Pulmonary TB include:
Special airborne precautions, including isolation in a negative pressure isolation room, and appropriate air handling.
Staff should wear appropriate personal protection devices, and close door behind them.
Staff should remove personal protection devices before exiting anteroom and sanitize hands after leaving room. See infection control module details, and CDC, (2005). Guidelines for preventing the transmission of My cobacterium, 2005.
Murphy, R.A. (2008) The emerging crisis of drug-resistant tuberculosis in South Africa: Lessons from New York City. Clinical Infectious Diseases 46, 1729-1732
CDC. (2003). Treatment of TB. American Thoracic Society, Centers for Disease Control and Prevention, and Infectious Disease Society of America. MMWR, 52 (RR-11),1-88.
Lashley, F.R., & Durham, J.D. (Eds.). (2007). Emerging infectious diseases: Trends and issues. 2nd edition. New York: Springer Publishing Co.
Mukherjee, J.S., Rich, M.L., Socci, A. R. et al. (2004). Programers and principles in treatment of multidrug- resistant tuberculosis. Lancet, 363, 474-481.
CDC (2008). Trends in tuberculosis- United States, 2007. MMWR 57, 281-285.
CDC (2005) Guidelines for preventing the transmission of tuberculosis; healthcare settings, 2005. MMWR,54,1-141.
Yew, W.W. and Leung, C.C. (2008) Management of multidrug-resistant tuberculosis: Update 2007. Respirology, 13, 21-46.